Evidence map›Paper›PMID 31582998›Full record

ArticleIranian journal of pathology2019

Prostate Cancer with Intraluminal Inclusions: the Association of the Immunophenotype with Grade Score.

Artem Pidddubnyi, Anatolii Romaniuk, Inna-Margaryta Radomychelski, Yuliia Moskalenko, Roman A Moskalenko

Open access · greenAbstract read
In one paragraph

Article in Iranian journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Short histological kaleidoscope - recent findings in histology. Part II.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Artem PidddubnyiDepartment of Pathology, Medical Institute, Sumy State University, Sumy, Ukraine.
Anatolii RomaniukDepartment of Pathology, Medical Institute, Sumy State University, Sumy, Ukraine.
Inna-Margaryta RadomychelskiDepartment of Pathology, Medical Institute, Sumy State University, Sumy, Ukraine.
Yuliia MoskalenkoDepartment of Surgery and Oncology, Medical Institute, Sumy State University, Sumy, Ukraine.
Roman A MoskalenkoDepartment of Pathology, Medical Institute, Sumy State University, Sumy, Ukraine.
Sumy State University · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

objectiveTo study the immunophenotype of prostate cancer (PC) with the presence and absence of intraluminal inclusions (IIn), depending on the grade score.

methodsA total of 30 PC samples with IIn (group E) and 30 PC samples without them (group C) were studied. These groups were divided into 2 subgroups, depending on the grade of malignancy, which was determined according to the Gleason score as moderate and high-grade tumors. Macroscopic analysis, hematoxylin-eosin staining, immunohistochemistry (androgen receptors, p53 and Bax proteins, Hsp70 and Hsp90, CD68, VEGF, OSN, MMP-1) were used.

resultsThe expression level of VEGF was higher in the more differentiated tumors of the control group (

conclusionthe presence of IIn in the PC samples of group E promotes tissue remodeling with mechanical trauma, chronic inflammation, and fibrosis development. The presence of IIn in PC leads to the increase of OSN, CD68 and Bax expression and decrease of Hsp90 and VEGF expression. High expression of p53 and MMP-1 and low expression of OSN and VEGF was identified as a characteristic of high-grade tumors.

Indexed as

Corpora amylaceaGrade scoreImmunohistochemistryProstate cancerProstatic calculi

Identifiers

PMID31582998
PMCPMC6742736
OpenAlexW2974554798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.